Answers are grounded in this paper and cite their sources.
Background Osteoporosis is a bone disease characterized by reduced bone mass and microstructural deterioration, leading to increased fragility and fracture risk, which significantly impairs patient health and quality of life. Although SMAD family member 5 (SMAD5) has been reported to be downregulated in osteoporosis and to facilitate osteogenic differentiation, its underlying mechanisms remain poorly defined. Methods Human bone marrow mesenchymal stem cells (hBMSCs) were characterized using flow cytometry. Protein expression was examined by Western blot, and proliferation was measured via EdU assay. Osteogenic differentiation was induced using dexamethasone, β-glycerophosphate, and ascorbic acid, and assessed through alkaline phosphatase and alizarin red staining. SMAD5-interacting molecules were identified using UbiBrowser, STRING, BioGRID, and DeeP-PLA databases. Interactions between NEDD4 and SMAD5, and between SMAD5 and HDAC1, were confirmed by co-immunoprecipitation (Co-IP). Results SMAD5 knockdown inhibited hBMSC proliferation, early osteogenic differentiation, and late mineralization. NEDD4 promoted SMAD5 ubiquitination and degradation, while SMAD5 overexpression reversed the inhibitory effect of NEDD4 on osteogenesis. HDAC1 deacetylated SMAD5, and SMAD5 upregulation alleviated the suppression of osteogenic differentiation caused by HDAC1 overexpression. Conclusion NEDD4 and HDAC1 independently reduce SMAD5 protein levels and inhibit osteogenic differentiation in hBMSCs, via mediating ubiquitin-dependent degradation and deacetylation of SMAD5 respectively.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: